drugset / Trial / NCT00021749
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
Timeline
- Start
- 2001-01
- Primary completion
- 2003-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | oblimersen sodium | Antisense oligonucleotide | 3 mg/kg | Intravenous |
| Subject | oblimersen sodium | Antisense oligonucleotide | 7 mg/kg | Intravenous |